The Justice Department and Drug Enforcement Administration announced April 23 that FDA-approved marijuana products and medical marijuana products covered by a qualifying state-issued license have been moved to Schedule III of the Controlled Substances Act, a significant loosening of federal restrictions on the drug for medical use.
The order, issued by Acting Attorney General Todd Blanche, carries out President Donald Trump's Dec. 18, 2025 executive order calling for expanded research into medical marijuana and cannabidiol.
Recent comments
4 weeks 1 day ago
4 weeks 4 days ago
12 weeks 5 days ago
13 weeks 6 days ago
14 weeks 4 days ago
19 weeks 6 days ago
26 weeks 2 days ago
26 weeks 2 days ago
29 weeks 3 days ago
30 weeks 2 days ago